Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL

Rituximab, Ifosfamide, Mitoxantrone Liposome, Etoposide (Modified R-MINE) Regimen vs. Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) Regimen in the Treatment of Late Relapsed Diffuse Large B-cell Lymphoma: A Multicenter, Open, Randomized, Controlled, Phase II Study

This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R - MINE plan or R - GemOx treatment. Each cycle was 3 weeks (21 days) for a total of 4 cycles. Subjects assigned to each signed informed consent to screening, screening, in the center of the study determined in accordance with the order signed informed consent. Before the start of the trial, the number of random seeds was set by the statistician, and the block randomization method was used to generate the subject random table using R 4.3.3 (or above). The random ratio between the modified R-mine group and the R-Gemox group was 1:1. After the investigator determined that the subjects were screened successfully, the subjects were randomly numbered according to the order in which the eligible subjects were screened successfully. The intervention was performed by the principal investigator or by someone designated by the principal investigator. Study includes screening period (the first 28 days), treatment period (plan 4 cycles, treatment after 2 cycles enhanced CT/MRI or PET - CT mid-term efficacy, PET - CT curative effect evaluation) after treatment, follow-up (follow-up curative effect, safety and survival follow-up follow-up). Participants provided written informed consent and underwent baseline examinations during the screening period. Participants who met the inclusion criteria and none of the exclusion criteria entered the treatment period. All the study participants completed protocol-specified examinations during the course of treatment to observe efficacy and safety. The end of the treatment period was followed by the follow-up period.

Study Overview

• Status: Not yet recruiting
• Conditions: DLBCL - Diffuse Large B Cell Lymphoma
• Intervention / Treatment: Drug: Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide; Drug: Rituximab+Gemcitabine+Oxaliplatin

• Study Type: Interventional
• Enrollment (Estimated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Wei Xu; Phone Number: 025-68306034; Email: xuwei10000@hotmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• They voluntarily participated in the study and signed the informed consent.
• Age 18 or higher;
• Expected survival time for 3 months or more;
• The histopathological diagnosed late relapsed (> 12 months) diffuse large B cell lymphoma;
• Must have at least a Lugano 2014 standard can be evaluation or measurable lesions: lymph node lesions, measurable lymph nodes should be diameter > 1.5 cm; Non-lymph node lesions, measurable extranodal lesions should be diameter > 1.0 cm;
• ECOG score 0 to 2 points;
• Bone marrow function: neutrophil count >= 1.5 x 10^9 / L, platelet count >= 75 x 10^9 / L, and hemoglobin >= 80 g/L (neutrophil count may be extended to >= 1.0 x 10^9 / L, the platelet count can be extended to >= 50 x 10^9 / L, and hemoglobin can be extended to >= 75 g/L in patients with bone marrow involvement);
• Liver and kidney function: serum creatinine acuities were <= 1.5 times the upper limit of normal (ULN) value; AST and ALT <= 2.5 times the ULN(<= 5 times the upper limit of normal in patients with liver invasion); Total bilirubin <= 1.5 times the ULN (<= 3 times the upper limit of normal in patients with liver invasion);
• Blood coagulation function: International standardization Ratio (International Normalized thewire, INR) <= 1.5 x ULN; Prothrombin Time (PT), Activated PartialThromboplastin Time (APTT) <= 1.5×ULN (unless receiving anticoagulant therapy, And PT and APTT at screening were within the expected range for anticoagulant therapy).

Exclusion Criteria:

• Previous history of antitumor therapy meeting any of the following conditions:

  1. Prior treatment with mitoxantrone or liposomal mitoxantrone;
  2. Prior treatment with doxorubicin or other anthracyclines, with a total cumulative doxorubicin dose >360 mg/m² (for other anthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin);
  3. Prior autologous hematopoietic stem cell transplantation within 100 days before the first dose, or a history of allogeneic hematopoietic stem cell transplantation;
  4. Prior antitumor therapy (including chemotherapy, targeted therapy, hormone therapy, traditional Chinese medicine with antitumor activity, etc.) or participation in other clinical trials involving investigational drugs within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of the study drug.
• Hypersensitivity to any study drug or its components;
• Uncontrolled systemic diseases (e.g., progressive infections, uncontrolled hypertension, diabetes, etc.);

• Cardiac function and diseases meeting any of the following conditions:

  1. Long QTc syndrome or QTc interval >480 ms;
  2. Complete left bundle branch block, complete right bundle branch block with left anterior fascicular block, type II second-degree or third-degree atrioventricular block;
  3. Severe, uncontrolled arrhythmia requiring medication;
  4. New York Heart Association Class ≥ III;
  5. History of acute myocardial infarction, unstable angina, severe unstable ventricular arrhythmia, or any other arrhythmia requiring treatment within 6 months before enrollment; history of clinically significant pericardial disease; or electrocardiographic evidence of acute ischemic or active conduction system abnormalities.
• Active hepatitis B or C infection (hepatitis B surface antigen positive with HBV DNA >1×10³ copies/mL; HCV RNA >1×10³ copies/mL);
• Human immunodeficiency virus (HIV) infection (HIV antibody positive);
• History or concurrent presence of other malignancies (except for effectively controlled non-melanoma skin basal cell carcinoma, in situ carcinoma of the breast/cervix, and other malignancies effectively controlled without treatment in the past five years);
• Presence of primary or secondary central nervous system (CNS) lymphoma or a history of CNS lymphoma at enrollment;
• Pregnant or lactating women, and patients of childbearing potential unwilling to use contraception;
• Requirement for systemic corticosteroid therapy or other immunosuppressive therapy due to a medical condition within 14 days before the start of study treatment [topical use (ocular, intra-articular, intranasal, and inhaled corticosteroids with minimal systemic absorption) is permitted; short-term (≤7 days) corticosteroid use for prophylaxis (e.g., contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is permitted];
• Other conditions deemed by the investigator to be unsuitable for participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: R-GemOx	Drug: Rituximab+Gemcitabine+Oxaliplatin; Rituximab 375 mg/m^2, d0; Gemcitabine 1000 mg/m^2, d1; Oxaliplatin 100 mg/m^2, d1; Every 21 days as one cycle, and 4 cycles were planned.
Experimental: modified R-MINE	Drug: Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide; Rituximab 375 mg/m^2, d0; Ifosfamide 1.33 g/m^2, d1-3 (equal dose of mesna rescue); Mitoxantrone hydrochloride liposome 12mg/m^2, d1; Etoposide 65 mg/m^2, d1-3; Every 21 days as one cycle, and 4 cycles were planned.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete response rate (CRR)	Response is assessed according to the lugano criteria.	every 2 cycles, up to 4 cycles (each cycle is 21 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR)	Response is assessed according to the lugano criteria.	every 2 cycles, up to 4 cycles (each cycle is 21 days)
Duration of response (DoR)	The time from the first assessment of CR or PR for the tumor to the first assessment of recurrence or PD or death from any cause.	2 years
Progression-free survival (PFS)	PFS was defined as the time between randomization and the first date of progression, relapse, or death from any cause.	2 years
Overall survival (OS)	From the date of randomization to date of death, irrespective of cause.	2 years
Adverse events (AEs)	The incidence, type, and severity of adverse events (graded according to CTCAE v5.0), and their relationship to the study treatment.	From the start of treatment to 28 days after the end of treatment.

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital with Nanjing Medical University
• Investigators: Principal Investigator: Wei Xu, The first Affiliated Hospital of Nanjing Medical University(JiangSu Province Hospital); Principal Investigator: Jinhua Liang, The first Affiliated Hospital of Nanjing Medical University(JiangSu Province Hospital)

Study record dates

Study Major Dates

• Study Start (Estimated): February 25, 2026
• Primary Completion (Estimated): October 30, 2027
• Study Completion (Estimated): December 30, 2029

Study Registration Dates

• First Submitted: December 17, 2025
• First Submitted That Met QC Criteria: January 28, 2026
• First Posted (Actual): February 5, 2026

Study Record Updates

• Last Update Posted (Actual): February 5, 2026
• Last Update Submitted That Met QC Criteria: January 28, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: DLBCL; Mitoxantrone Hydrochloride liposomal
• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Lymphatic Diseases; Histiocytic Disorders, Malignant; Histiocytosis; Hemic and Lymphatic Diseases; Dendritic Cell Sarcoma, Interdigitating
• Other Study ID Numbers: CSPC-DED-DLBCL-K16

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No